Evidence map›Paper›PMID 32574556›Full record

ArticleDevelopmental cell2020

Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex.

Laurent Fattet, Hae-Yun Jung, Mike W Matsumoto, Brandon E Aubol, Aditya Kumar, Joseph A Adams, Albert C Chen, Robert L Sah, Adam J Engler, Elena B Pasquale and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Developmental cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 172 papers.

0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

172 citing papers in PubMed, 240 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. A systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

112 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Laurent FattetDepartment of Pharmacology, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Hae-Yun JungDepartment of Pharmacology, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Mike W MatsumotoCancer Center, Sanford Burnham Prebys Medical Discovery Institute, San Diego, La Jolla, CA 92037, USA.
Brandon E AubolDepartment of Pharmacology, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Aditya KumarDepartment of Bioengineering, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Joseph A AdamsDepartment of Pharmacology, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Albert C ChenDepartment of Bioengineering, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Robert L SahDepartment of Bioengineering, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Adam J EnglerDepartment of Bioengineering, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Elena B PasqualeCancer Center, Sanford Burnham Prebys Medical Discovery Institute, San Diego, La Jolla, CA 92037, USA.
Jing YangDepartment of Pharmacology, University of California, San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Moores Cancer Center, Department of Pediatrics, University of California, San Diego, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, USA. Electronic address: jingyang@ucsd.edu.
University of California, San Diego · USDiscovery Institute · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
Regulation of Tumor Invasion and Metastasis by Matrix StiffnessR01CA174869 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jing Yang · 2015 to 2026
$4.3M
Apical-basal polarity in tumor progression and metastasisR01CA236386 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YANG, JING · 2019 to 2023
$1.9M
Biomaterial Mimicry of Dynamic Matrix Stiffening During Tumor ProgressionR01CA206880 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ENGLER, ADAM J, YANG, JING · 2016 to 2020
$1.8M
Regulation of Tumor Invasion by Twist1R01CA168689 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YANG, JING · 2012 to 2016
$1.7M
NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA168689NCI NIH HHS R01 CA174869NCI NIH HHS R01 CA206880NCI NIH HHS R01 CA236386
6 · The paper itself

Abstract

Mechanical cues from the extracellular matrix (ECM) regulate various cellular processes via distinct mechanotransduction pathways. In breast cancer, increased ECM stiffness promotes epithelial-to-mesenchymal transition (EMT), cell invasion, and metastasis. Here, we identify a mechanosensitive EPHA2/LYN protein complex regulating EMT and metastasis in response to increasing ECM stiffness during tumor progression. High ECM stiffness leads to ligand-independent phosphorylation of ephrin receptor EPHA2, which recruits and activates the LYN kinase. LYN phosphorylates the EMT transcription factor TWIST1 to release TWIST1 from its cytoplasmic anchor G3BP2 to enter the nucleus, thus triggering EMT and invasion. Genetic and pharmacological inhibition of this pathway prevents breast tumor invasion and metastasis in vivo. In human breast cancer samples, activation of this pathway correlates with collagen fiber alignment, a marker of increasing ECM stiffness. Our findings reveal an EPHA2/LYN/TWIST1 mechanotransduction pathway that responds to mechanical signals from the tumor microenvironment to drive EMT, invasion, and metastasis.

Indexed as

AnimalsBreast NeoplasmsCell AdhesionCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionExtracellular MatrixHumansMammary Neoplasms, AnimalMechanotransduction, CellularMiceNuclear ProteinsReceptor, EphA2Tumor MicroenvironmentTwist-Related Protein 1Nuclear ProteinsReceptor, EphA2TWIST1 protein, humanTwist-Related Protein 1ECM stiffness and breast cancerEMTEPHA2epithelial-mesenchymal transitionLYNmatrix stiffnessmechanotransductionmetastasisTWIST1

Identifiers

PMID32574556
PMCPMC7423770
OpenAlexW3035967781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.